Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.

Accepted 2024-01-03 00:00:00 ET · period of report 2024-01-02 · accession 0001725160-24-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-01-03	2024-01-02	ZNTL	Lackner Mark	CSO	A - Grant	$0.00	+40.0K	56.3K	+245%	$0
D	2024-01-03	2024-01-02	ZNTL	Lackner Mark	CSO	A - Grant	$0.00	+60.0K	60.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-01-02	A	A	40,000	$0.00	56,313	D	—	—	(F1) Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of December 31, 2023, subject to the Reporting Person's continuing service with the Issuer.
2	Derivative	Stock Option (Right to Buy)	2024-01-02	A	A	60,000	$0.00	60,000	D	$15.99 · — to 2034-01-02	60,000 Common Stock	(F2) The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.